Which medications in the drug class Antineoplastics, Monoclonal Antibody are used in the treatment of Hairy Cell Leukemia?

Updated: Sep 16, 2018
  • Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan, MD, FRCP, FACP  more...
  • Print
Answer

Antineoplastics, Monoclonal Antibody

Moxetumomab pasudotox is the first monoclonal antibody (mAb) approved for hairy cell leukemia. After the mAb binds to CD22, the molecule is internalized; internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.

Moxetumomab pasudotox (Lumoxiti, moxetumomab pasudotox-tdfk)

Anti-CD22 recombinant immunotoxin. Indicated for adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior systemic therapies, including a purine nucleoside analog.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!